Opko Health Inc. (OPK) Forecasted to Post Q3 2017 Earnings of ($0.01) Per Share
Opko Health Inc. (NYSE:OPK) – Research analysts at Jefferies Group cut their Q3 2017 earnings estimates for shares of Opko Health in a note issued to investors on Tuesday. Jefferies Group analyst B. Couillard now anticipates that the firm will post earnings of ($0.01) per share for the quarter, down from their previous estimate of $0.01. Jefferies Group currently has a “Hold” rating and a $10.00 target price on the stock.
Opko Health (NYSE:OPK) last posted its earnings results on Monday, November 7th. The company reported ($0.03) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.03). The business had revenue of $298 million for the quarter, compared to analyst estimates of $322 million. During the same quarter last year, the business earned $0.25 earnings per share. Opko Health’s revenue was up 108.4% on a year-over-year basis.
Several other equities research analysts have also recently issued reports on the stock. Zacks Investment Research raised shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Tuesday, October 25th. Oppenheimer Holdings Inc. reissued a “hold” rating on shares of Opko Health in a research report on Monday, October 10th. Finally, JPMorgan Chase & Co. set a $14.00 price target on shares of Opko Health and gave the company a “buy” rating in a research report on Tuesday, August 9th. Five analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $13.20.
Opko Health (NYSE:OPK) traded down 0.94% during midday trading on Wednesday, hitting $9.49. The stock had a trading volume of 899,305 shares. Opko Health has a 12 month low of $7.12 and a 12 month high of $11.85. The stock has a market cap of $5.22 billion and a price-to-earnings ratio of 39.71. The stock has a 50 day moving average of $9.93 and a 200 day moving average of $9.89.
In other news, CEO Phillip Md Et Al Frost purchased 10,000 shares of the company’s stock in a transaction dated Monday, August 15th. The shares were acquired at an average cost of $10.07 per share, for a total transaction of $100,700.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $30,904,336.57. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Hedge funds have recently added to or reduced their stakes in the stock. Bridger Management LLC acquired a new stake in Opko Health during the first quarter valued at approximately $13,863,000. First Trust Advisors LP raised its stake in Opko Health by 164.8% in the second quarter. First Trust Advisors LP now owns 1,526,964 shares of the company’s stock valued at $14,262,000 after buying an additional 950,355 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its stake in Opko Health by 90.7% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,897,107 shares of the company’s stock valued at $17,687,000 after buying an additional 902,185 shares in the last quarter. State Street Corp raised its stake in Opko Health by 11.6% in the second quarter. State Street Corp now owns 7,454,724 shares of the company’s stock valued at $69,627,000 after buying an additional 773,867 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. raised its stake in Opko Health by 7.9% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 8,559,707 shares of the company’s stock valued at $90,647,000 after buying an additional 624,740 shares in the last quarter.
About Opko Health
OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.
Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.